Cancers

Journal Browser

► Journal Browser

Novel Drugs for Treating Gynecologic Cancers: 2nd Edition

Share This Special Issue

Special Issue Editors

Special Issue Information

Dear Colleagues,

This Special Issue is titled “Novel Drugs for Treating Gynecologic Cancers: 2nd Edition”.

Gynecologic cancer treatment has reached a major turning point thanks to the development of molecularly targeted agents and immune-checkpoint inhibitors.

In particular, in ovarian cancer treatment, testing for BRCA and HRD status is expected to further improve prognosis by combining molecular targeted agents with different mechanisms of action.

This Special Issue aims to collect original research studies and review articles (either systematic or discursive), clinical trials, and short communications adding to the current knowledge and showing potential future approaches of novel agents for gynecologic cancers.

Prof. Dr. Tadahiro Shoji
Prof. Dr. Hiroaki Itamochi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.

Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.

Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.

External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.

Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

14 pages, 1860 KB

Open AccessArticle

Comparative Effectiveness of Bevacizumab and Olaparib Maintenance Therapy in Platinum-Sensitive Recurrent Ovarian Cancer: A Real-World Study with Exploratory Evaluation of Dose Reduction

by Shunsuke Tatsuki, Tadahiro Shoji, Ami Jo, Nanako Jonai, Yohei Chiba, Sho Sato, Eriko Takatori, Yoshitaka Kaido, Takayuki Nagasawa, Masahiro Kagabu, Takeshi Aida, Fumiharu Miura and Tsukasa Baba

Cancers 2026, 18(9), 1332; https://doi.org/10.3390/cancers18091332 - 22 Apr 2026

Viewed by 281

Abstract

Objective: To compare real-world PFS between BEV and OLA as maintenance therapy for PSROC, with an exploratory evaluation of clinical outcomes after OLA dose reduction. Methods: This retrospective multicenter study included 101 patients with first platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer who achieved a response to platinum-based chemotherapy and then received maintenance therapy. Patients were classified into three groups: BEV (n = 34), standard-dose OLA (n = 31), and dose-reduced OLA (n = 36). The primary endpoint was PFS; secondary endpoints were OS and adverse events. Survival outcomes were evaluated using Kaplan–Meier methods and Cox proportional hazards models. Results: In the primary comparison of all OLA-treated patients versus BEV, OLA was associated with longer PFS (HR 0.48, 95% CI 0.29–0.77), with median PFS of 19 months versus 16 months, respectively. OS did not differ significantly between groups (HR 0.60, 95% CI 0.34–1.05). In exploratory subgroup analyses, patients who underwent OLA dose reduction had numerically longer PFS than those who remained on the full dose; however, this comparison is vulnerable to time-dependent and selection biases and should be interpreted cautiously. Grade ≥ 3 hematologic toxicities were more frequent in the OLA groups but were clinically manageable. Conclusions: In real-world practice, OLA was associated with longer PFS than BEV in PSROC. Clinically necessary dose reduction appeared feasible without an obvious loss of benefit, although this finding requires cautious interpretation. Full article

(This article belongs to the Special Issue Novel Drugs for Treating Gynecologic Cancers: 2nd Edition)

► Show Figures

Journal Menu

Journal Browser

Novel Drugs for Treating Gynecologic Cancers: 2nd Edition

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Benefits of Publishing in a Special Issue

Published Papers (1 paper)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI